Alexis Kelly1, Alexander Pai1, Ben Lertsakdadet1, Bernard Choi1,2,3, Kristen M Kelly1,4. 1. Beckman Laser Institute and Medical Clinic, University of California, 1002 Health Sciences Rd, Irvine, California, 92617. 2. Department of Biomedical Engineering, Henry Samueli School of Engineering, University of California, 3120 Natural Sciences II, Irvine, California, 92697-2715. 3. Edwards Life Sciences Center for Advanced Cardiovascular Technology, University of California, 2400 Engineering Hall, Irvine, California, 92697-2730. 4. Department of Dermatology, University of California, 118 Medical Surge, Irvine, California, 92697-2400.
Abstract
BACKGROUND AND OBJECTIVE: Oxymetazoline, an α-1A agonist, is approved by the United States Food and Drug Administration (FDA) for treatment of persistent facial erythema associated with rosacea and induces vasoconstriction by interacting with α receptors. The objective of our study was to study the microvascular effects of oxymetazoline and pulsed dye laser (PDL). MATERIALS AND METHODS: A dorsal window chamber was surgically installed on 20 mice. Each animal was assigned to one of four experimental groups: saline alone, oxymetazoline alone (10 μl applied once daily × 7 days), saline + PDL (saline applied 5 minutes before PDL irradiation [10 mm spot, 1.5 ms pulse duration, 7 J/cm2 delivered to epidermis]), or oxymetazoline + PDL (10 μl oxymetazoline applied 5 minutes before PDL and then once daily × 7 days). Brightfield and laser speckle imaging were performed for 7 days to monitor vascular architectural and functional changes. RESULTS: We observed persistent blood flow in all of the saline-only and oxymetazoline-only experiments. A higher rate of vascular shutdown was observed with oxymetazoline + PDL (66.7%) compared with saline + PDL alone (16.7%). Oxymetazoline application increased venule diameter at 5 minutes post-application and decreased both arteriole and venule diameters at 60 minutes post-application. CONCLUSION: The combination protocol of oxymetazoline + PDL induces persistent vascular shutdown observed 7 days after irradiation. This result may be associated with the acute vascular effects of oxymetazoline. Oxymetazoline + PDL should be evaluated as a treatment for cutaneous vascular disease, including rosacea and port wine birthmarks. Lasers Surg. Med.
BACKGROUND AND OBJECTIVE:Oxymetazoline, an α-1A agonist, is approved by the United States Food and Drug Administration (FDA) for treatment of persistent facial erythema associated with rosacea and induces vasoconstriction by interacting with α receptors. The objective of our study was to study the microvascular effects of oxymetazoline and pulsed dye laser (PDL). MATERIALS AND METHODS: A dorsal window chamber was surgically installed on 20 mice. Each animal was assigned to one of four experimental groups: saline alone, oxymetazoline alone (10 μl applied once daily × 7 days), saline + PDL (saline applied 5 minutes before PDL irradiation [10 mm spot, 1.5 ms pulse duration, 7 J/cm2 delivered to epidermis]), or oxymetazoline + PDL (10 μl oxymetazoline applied 5 minutes before PDL and then once daily × 7 days). Brightfield and laser speckle imaging were performed for 7 days to monitor vascular architectural and functional changes. RESULTS: We observed persistent blood flow in all of the saline-only and oxymetazoline-only experiments. A higher rate of vascular shutdown was observed with oxymetazoline + PDL (66.7%) compared with saline + PDL alone (16.7%). Oxymetazoline application increased venule diameter at 5 minutes post-application and decreased both arteriole and venule diameters at 60 minutes post-application. CONCLUSION: The combination protocol of oxymetazoline + PDL induces persistent vascular shutdown observed 7 days after irradiation. This result may be associated with the acute vascular effects of oxymetazoline. Oxymetazoline + PDL should be evaluated as a treatment for cutaneous vascular disease, including rosacea and port wine birthmarks. Lasers Surg. Med.
Authors: Wangcun Jia; Nadia Tran; Victor Sun; Marko Marinček; Boris Majaron; Bernard Choi; J Stuart Nelson Journal: Lasers Surg Med Date: 2012-01-24 Impact factor: 4.025
Authors: Linda Stein-Gold; Leon Kircik; Zoe Diana Draelos; Philip Werschler; Janet DuBois; Edward Lain; Leslie Baumann; David Goldberg; Joely Kaufman; Emil Tanghetti; Gurpreet Ahluwalia; Nancy Alvandi; Emily Weng; David Berk Journal: J Drugs Dermatol Date: 2018-11-01 Impact factor: 2.114
Authors: Austin J Moy; Sean M White; Elmer S Indrawan; Justin Lotfi; Matthew J Nudelman; Samantha J Costantini; Nikita Agarwal; Wangcun Jia; Kristen M Kelly; Brian S Sorg; Bernard Choi Journal: Microvasc Res Date: 2011-07-23 Impact factor: 3.514
Authors: Guillermo Aguilar; Bernard Choi; Mans Broekgaarden; Owen Yang; Bruce Yang; Pedram Ghasri; Jennifer K Chen; Rick Bezemer; J Stuart Nelson; Anne Margreet van Drooge; Albert Wolkerstorfer; Kristen M Kelly; Michal Heger Journal: Ann Biomed Eng Date: 2011-10-21 Impact factor: 3.934
Authors: Vani Yepuri; Anant D Patil; Klaus Fritz; Carmen Salavastru; George Kroumpouzos; Steven Paul Nisticò; Domenico Piccolo; Ahmed Sadek; Ashraf Badawi; Martin Kassir; Michael H Gold; Stephan Große-Büning; Stephan Grabbe; Mohamad Goldust Journal: Dermatol Ther (Heidelb) Date: 2021-09-25